PARP Inhibitors in Prostate Cancer

Anticancer Res. 2021 Feb;41(2):551-556. doi: 10.21873/anticanres.14807.

Abstract

Treatment of metastatic prostate cancer has evolved significantly over the past decade. Palliative therapy has, historically, consisted of androgen deprivation, chemotherapy and different radiation therapy approaches. More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in the outcome of patients with metastatic prostate cancer who harbor certain genetic mutations. This concise review focuses on the 3 PARP inhibitors that have shown activity in metastatic prostate cancer.

Keywords: PARP; PCa; mCRPC; prostate adenocarcinoma; prostate cancer; review.

Publication types

  • Review

MeSH terms

  • Animals
  • BRCA1 Protein / genetics
  • BRCA2 Protein / genetics
  • Genetic Predisposition to Disease
  • Humans
  • Indazoles / adverse effects
  • Indazoles / therapeutic use*
  • Indoles / adverse effects
  • Indoles / therapeutic use*
  • Male
  • Mutation
  • Neoplasm Metastasis
  • PTEN Phosphohydrolase / genetics
  • Phenotype
  • Phthalazines / adverse effects
  • Phthalazines / therapeutic use*
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Piperidines / adverse effects
  • Piperidines / therapeutic use*
  • Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / enzymology
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / pathology
  • Treatment Outcome

Substances

  • BRCA1 Protein
  • BRCA1 protein, human
  • BRCA2 Protein
  • BRCA2 protein, human
  • Indazoles
  • Indoles
  • Phthalazines
  • Piperazines
  • Piperidines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • rucaparib
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • niraparib
  • olaparib